ID

21397

Beschreibung

NCT00340080 / VIIV-CNA106030 A phase IV, randomised, multicentre, double-blind, study to evaluate the clinical utility of prospective genetic screening (HLA-B*5701) for susceptibility to abacavir hypersensitivity Assessment: Expanded PGx-Pharmacogenetic Research Medicine: abacavir, Condition: Infection, Human Immunodeficiency Virus, Phase: 4, Clinical Study ID: CNA106030, Sponsor: ViiV

Stichworte

  1. 19/4/17 19/4/17 -
Hochgeladen am

19 de abril de 2017

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY-NC 3.0

Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Genetic Screening For HLA-B*5701 in Patients with HIV Expanded PGx-Pharmacogenetic Research NCT00340080

Genetic Screening For HLA-B*5701 Expanded PGx-Pharmacogenetic Research NCT00340080

Expanded PGx-Pharmacogenetic Research
Beschreibung

Expanded PGx-Pharmacogenetic Research

Alias
UMLS CUI-1
C2347500
UMLS CUI-2
C0008976
Subject Identifier
Beschreibung

Subject Identifier

Datentyp

text

Alias
UMLS CUI [1]
C2348585
Has informed consent been obtained for expanded PGx-Pharmacogenetic research on safety/tolerability of HAART?
Beschreibung

informed consent

Datentyp

text

Alias
UMLS CUI [1]
C0021430
If Yes, record the date informed consent obtained for Expanded PGx-Pharmacogenetic research on safety/tolerability of HAART
Beschreibung

date informed consent obtained

Datentyp

date

Alias
UMLS CUI [1,1]
C0514044
UMLS CUI [1,2]
C0011008
If No, check 􏰀one reason:
Beschreibung

reason informed consent not obtained

Datentyp

integer

Alias
UMLS CUI [1,1]
C0392360
UMLS CUI [1,2]
C0021430
UMLS CUI [1,3]
C1882120
If other reason please specify
Beschreibung

reason informed consent not obtained

Datentyp

text

Alias
UMLS CUI [1,1]
C0392360
UMLS CUI [1,2]
C0021430
UMLS CUI [1,3]
C1882120
Has subject withdrawn consent for expanded PGx-Pharmacogenetic research on safety/tolerability of HAART?
Beschreibung

Withdrawal of consent

Datentyp

text

Alias
UMLS CUI [1]
C1707492

Ähnliche Modelle

Genetic Screening For HLA-B*5701 Expanded PGx-Pharmacogenetic Research NCT00340080

Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
Expanded PGx-Pharmacogenetic Research
C2347500 (UMLS CUI-1)
C0008976 (UMLS CUI-2)
Subject Identifier
Item
Subject Identifier
text
C2348585 (UMLS CUI [1])
Item
Has informed consent been obtained for expanded PGx-Pharmacogenetic research on safety/tolerability of HAART?
text
C0021430 (UMLS CUI [1])
Code List
Has informed consent been obtained for expanded PGx-Pharmacogenetic research on safety/tolerability of HAART?
CL Item
Yes (Y)
CL Item
No (N)
date informed consent obtained
Item
If Yes, record the date informed consent obtained for Expanded PGx-Pharmacogenetic research on safety/tolerability of HAART
date
C0514044 (UMLS CUI [1,1])
C0011008 (UMLS CUI [1,2])
Item
If No, check 􏰀one reason:
integer
C0392360 (UMLS CUI [1,1])
C0021430 (UMLS CUI [1,2])
C1882120 (UMLS CUI [1,3])
Code List
If No, check 􏰀one reason:
CL Item
Subject declined (1)
CL Item
Subject not asked by Investigator (2)
CL Item
Other (3)
reason informed consent not obtained
Item
If other reason please specify
text
C0392360 (UMLS CUI [1,1])
C0021430 (UMLS CUI [1,2])
C1882120 (UMLS CUI [1,3])
Item
Has subject withdrawn consent for expanded PGx-Pharmacogenetic research on safety/tolerability of HAART?
text
C1707492 (UMLS CUI [1])
Code List
Has subject withdrawn consent for expanded PGx-Pharmacogenetic research on safety/tolerability of HAART?
CL Item
Yes (Y)
CL Item
No (N)

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video